I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Leave site
Roche and Genentech at

APAO 2026

We will be contributing to topics related to
-
01:05 AM
Duration 5mins China
Primary Results of the Phase-3 SatraGO-1 and SatraGO 2 Trials: Efficacy and Safety of Satralizumab▼ in Thyroid Eye Disease
Li Dongmei
03:05 AM
Duration 5mins Singapore
Comparative Efficacy of Faricimab▼ for the Treatment of Diabetic Macular Edema at 1 and 2 Years: A Systematic Literature Review and Network Meta-Analysis
Colin Tan
03:10 AM
Duration 5mins Malaysia
Effectiveness and Safety of Faricimab▼ in nAMD (Neovascular Age-Related Macular Degeneration) and DME (Diabetic Macular Edema) Eyes Beyond Year-1: UK FARWIDE-nAMD and FARWIDE-DME Study Results
Kenneth Fong
03:25 AM
Duration 5mins China
Faricimab▼ for PCV (Polypoidal Choroidal Vasculopathy): One-Year Ethnically Chinese Subgroup Results from Phase-3b/4 SALWEEN Trial
Ming Zhang
09:00 AM
Duration 5mins Singapore
Predictors of Extended Treatment Interval in DME (Diabetic Macular Edema) Patients Treated With Faricimab▼ in the Phase-3 YOSEMITE/RHINE Trials
Anna Tan
Duration 5mins Korea
Intraretinal and Subretinal Fluid Resolution With Vamikibart in Uveitic Macular Edema: Phase-1 DOVETAIL Exploratory Results
Iksoo Byon
09:30 AM
Duration 5mins Taiwan
Interleukin-6 Inhibition With Vamikibart in Patients With Uveitic Macular Edema: Data From Phase-3 MEERKAT and SANDCAT trials
Yih-Shiou Hwang
09:40 AM
Duration 5mins Taiwan
Machine Learning–Based 3D Volumetric Analysis of Pigment Epithelial Detachment Reduction With Faricimab▼ vs Aflibercept in TENAYA/LUCERNE
Ling Yeung
10:05 AM
Duration 5mins Thailand
Real-World Faricimab▼ Outcomes in nAMD (Neovascular Age-Related Macular Degeneration) and DME (Diabetic Macular Edema): The VOYAGER Study
Voraporn Chaikitmongkol
03:25 AM
Duration 5mins Singapore
Long-Term Efficacy and Safety of PDS (Port Delivery Platform With Ranibizumab) in Patients With nAMD (Neovascular Age-related Macular Degeneration): Results From the Ladder- and Archway-to-Portal Trials
Yuen Yew Sen
03:40 AM
Duration 5mins Australia
Association of Early Macular Leakage Resolution with Extended Dosing Intervals in Patients With RVO (Retinal Vein Occlusion): A Post-Hoc Analysis of the BALATON/COMINO Trials
Hemal Mehta
03:55 AM
Duration 5mins Korea
Impact of the Optimization of Surgical Procedure on the Incidence of Endophthalmitis and Associated Patient Outcomes in Port Delivery Platform with Ranibizumab Trials
SeJoon Woo
08:35 AM
Duration 5mins Korea
Baseline and Early Treatment Response Variables of Faricimab▼ Durability in Treatment-Naïve nAMD (Neovascular Age-Related Macular Degeneration)
JiHun Song
03:10 AM
Duration 5mins Hong Kong
Automated Quantification of Retinal Fluid in Patients with Diabetic Macular Edema: Analysis of Faricimab▼ vs Aflibercept in YOSEMITE/RHINE
Simon Szeto
03:50 AM
Duration 5mins Japan
Update on Faricimab▼ for Diabetic Macular Edema: New Clinical Features of Eyes in the RHONE-X Long-Term Extension Study
Toshinori Murata
04:00 AM
Duration 5mins Thailand
Faricimab▼ for Polypoidal Choroidal Vasculopathy: One-Year Results From the Phase-3b/4 SALWEEN Trial
Paisan Rumaviboonsuk
07:15 AM
Duration 5mins Taiwan
Impact of PDS (Port Delivery Platform With Ranibizumab) in Study Eyes vs Anti-VEGF (Vascular Endothelial Growth Factor) in Fellow-Eyes on Efficacy and Safety Outcomes in Bilateral DME (Diabetic Macular Edema) in Pagoda
Yi-Ting Hsieh
08:35 AM
Duration 5mins Hong Kong
Four-Year Outcomes of Faricimab▼ in Neovascular Age-Related Macular Degeneration: Safety and Efficacy From the AVONELLE-X Long-Term Extension Trial
Timothy Lai
09:15 AM
Duration 5mins Taiwan
Greater Anatomical Improvements With Faricimab▼ vs Aflibercept 8 Weeks After Injections: A TENAYA/LUCERNE Post-Hoc Analysis
Tai-Chi Lin
Coming soon